Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation

Table 2 Results representing the Cell cycle analysis of MFX and CFX treated MIA PaCa-2 cells

24 h	Sub G1	G1	S	G2	48 h	Sub G1	G1	S	G2
MIA PaCa-2	Sub G1	G1	S	G2	MIA PaCa-2	Sub G1	G1	S	G2
0 μg/ml	5 ± 0.5	53.8 ± 3.2	7.5 ± 1	33.7 ± 2.1	0 μg/ml	2.6 ± 0.5	67.1 ± 3	6.3 ± 1.2	24 ± 1.5
MFX 100 μg/ml	5.7 ± 0.35	48.2 ± 2.1	10.4 ± 1.1	35.7 ± 3.1	MFX 100 μg/ml	2.1 ± 1.1	63.7 ± 2.5	10.6 ± 0.9	23.6 ± 1
MFX 200 μg/ml	6.2 ± 0.4	60.6 ± 4	11 ± 1.2	22.2 ± 2.3	MFX 200 μg/ml	3.5 ± 2	54.3 ± 2	18.1 ± 0.8	24.1 ± 0.5
MFX 400 μg/ml	28 ± 1.5	49.1 ± 2.6	7.1 ± 1.5	15.8 ± 1.8	MFX 400 μg/ml	37.6 ± 2.1	40 ± 3.4	11 ± 1.2	11.4 ± 1.8
CFX 100 μg/ml	4.5 ± 0.6	63 ± 1.5	8.9 ± 2	23.6 ± 1.8	CFX 100 μg/ml	5.5 ± 1.7	51.5 ± 1.5	14.3 ± 0.6	28.7 ± 3
CFX 200 μg/ml	18.5 ± 2	55.2 ± 2.1	9.1 ± 1.3	17.2 ± 2.3	CFX 200 μg/ml	28.4 ± 1.9	52.8 ± 2	14 ± 1.1	4.8 ± 4.5
CFX 400 μg/ml	30.1 ± 2	48.1 ± 3	7.3 ± 2	14.5 ± 2.7	CFX 400 μg/ml	59.9 ± 1.1	32.2 ± 3.9	4.4 ± 2	3.5 ± 3.2

Values represent the percent of population in each phase. Values with significant changes have been highlighted with bold format

ISSN: 1471-2407